BioMarin Pharmaceutical Welcomes Ian T. Clark as New Board Chair Amid Leadership Transition

BioMarin's Board Leadership Transition

BioMarin Pharmaceutical Inc., a key player in the biotechnology industry, has announced a significant leadership change within its Board of Directors. On April 21, 2026, the company revealed that Ian T. Clark has been appointed as the Chair of the Board, transitioning from Richard A. Meier, who has decided to retire after a distinguished tenure that spans over two decades.

Ian T. Clark's appointment as Chair is contingent upon his election during the upcoming Annual Meeting of Stockholders scheduled for June 2, 2026. Mr. Clark, who joined the Board in 2025, is recognized for his extensive experience in governance and executive leadership within the global biopharmaceutical sector. His prior role as Chief Executive Officer of Genentech, along with his experience on various public biopharmaceutical boards, positions him as a strong leader for BioMarin.

In his statement, Clark expressed enthusiasm about stepping into the Chair role, particularly at a time when BioMarin is poised for growth. "With our recent acquisitions, we can significantly unlock value for all stakeholders, including employees, shareholders, and most importantly, our patients," he stated. This sentiment reflects the company's commitment to advancing its mission of providing innovative therapies for individuals with genetically defined conditions.

Richard Meier, the outgoing Chair, has made vital contributions to BioMarin’s growth and strategic direction since joining the Board in 2006. As a former Lead Independent Director, he has played a crucial role in improving the company's profitability, expanding its operating margin, and driving significant earnings growth. Reflecting on his time at BioMarin, Meier stated, "It has been an honor to serve on BioMarin's Board, and I am pleased to hand over the leadership to Ian, who is well-suited to guide the company forward."

Alexander Hardy, President and Chief Executive Officer of BioMarin, also expressed gratitude towards Meier for his impactful leadership. He welcomed Ian's experience and voiced optimism for the company’s trajectory under Clark's guidance. "We look forward to collaborating with Ian as we execute our global strategy in delivering essential therapies to patients," Hardy noted.

BioMarin, founded in 1997 and headquartered in San Rafael, California, focuses on developing and delivering therapies tailored for rare genetic disorders. The company is noted for its innovative approaches to drug discovery and development, having established a robust portfolio of approved therapies, alongside an exciting pipeline that showcases its commitment to addressing unmet medical needs.

As BioMarin continues its journey into the next chapter, the leadership transition signifies its readiness to build on the solid foundation laid by its leaders. The impending election of Ian T. Clark as Chair at the Annual Meeting highlights the strategic planning prioritize by the company, aiming for sustained success in the biopharmaceutical landscape.

The upcoming months will be pivotal for BioMarin as it navigates this leadership change, with the potential to further cement its position as a leader in the biotechnology field. With an experienced board and clear strategic vision, BioMarin is expected to continue delivering value to its stakeholders while keeping the needs of patients at the forefront.

For more information about BioMarin and its commitment to innovation in biotechnology, visit www.biomarin.com.